Focused On-demand Library for Sodium channel subunit beta-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for ion channels.

Fig. 1. The sreening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q07699

UPID:

SCN1B_HUMAN

Alternative names:

Alternative UPACC:

Q07699; Q5TZZ4; Q6TN97

Background:

Sodium channel subunit beta-1, encoded by the gene represented in the entry Q07699, is a regulatory subunit integral to the function of voltage-gated sodium channel complexes. These complexes are crucial in excitable membranes within the brain, heart, and skeletal muscle, influencing channel gating, inactivation rates, and surface expression. Additionally, this protein plays a pivotal role in neuronal migration and pathfinding during brain development, stimulating neurite outgrowth.

Therapeutic significance:

The protein's involvement in a spectrum of diseases, including Generalized epilepsy with febrile seizures plus 1, Brugada syndrome 5, Familial atrial fibrillation 13, and Developmental and epileptic encephalopathy 52, underscores its therapeutic significance. Understanding the role of Sodium channel subunit beta-1 could lead to novel therapeutic strategies for these conditions, highlighting the importance of targeted research in this area.